

Philip J Smith

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7931960/publications.pdf>

Version: 2024-02-01

30
papers

2,442
citations

687363

13
h-index

677142

22
g-index

54
all docs

54
docs citations

54
times ranked

3172
citing authors

#	ARTICLE	IF	CITATIONS
1	Inflammatory bowel disease clinical service recovery during the COVID-19 pandemic. <i>Frontline Gastroenterology</i> , 2022, 13, 77-81.	1.8	2
2	Twitter debate: controversies in liver transplantation. <i>Frontline Gastroenterology</i> , 2022, 13, 262-265.	1.8	3
3	Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 389-397.	1.3	39
4	Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. <i>Nature Communications</i> , 2022, 13, 1379.	12.8	48
5	Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1436-1446.	1.3	29
6	Halting the haematochezia. <i>Frontline Gastroenterology</i> , 2021, 12, 232-234.	1.8	0
7	Managing intestinal failure in inflammatory bowel disease - "when the drugs don't work". <i>Frontline Gastroenterology</i> , 2021, 12, 414-422.	1.8	0
8	Guideline review: Tofacitinib for adults with moderately to severely active ulcerative colitis - NICE guidance. <i>Frontline Gastroenterology</i> , 2021, 12, 133-136.	1.8	11
9	Occupational hazard in an immunosuppressed patient. <i>Frontline Gastroenterology</i> , 2021, 12, 74-76.	1.8	1
10	P98...Disease involution is common among paediatric Crohn's disease patients: a study from the biologic era. , 2021, , .		0
11	From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 88-89.	8.1	26
12	Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. <i>Gut</i> , 2021, 70, 865-875.	12.1	153
13	SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 218-224.	8.1	111
14	Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. <i>Gut</i> , 2021, 70, 1884-1893.	12.1	233
15	Moving house "moving medical teams: keeping control of my IBD. <i>Frontline Gastroenterology</i> , 2021, 12, 3-4.	1.8	1
16	PMO-16...Efficacy and safety of elective switching from intravenous to subcutaneous infliximab: A multi-centre cohort study. , 2021, , .		0
17	PMO-28...Efficacy of subcutaneous infliximab in perianal crohn's disease. , 2021, , .		0
18	Masquerading in the midgut: a rare diagnosis in a patient with recurrent abdominal pain. <i>Frontline Gastroenterology</i> , 2020, 11, 420-422.	1.8	1

#	ARTICLE	IF	CITATIONS
19	Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti- $\text{TNF}\alpha$ -refractory Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1341-1352.	3.7	46
20	Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic. <i>Frontline Gastroenterology</i> , 2020, 11, 343-350.	1.8	37
21	Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel. <i>Gut</i> , 2020, 69, gutjnl-2020-321927.	12.1	28
22	High Prevalence of Strongyloides among South Asian Migrants in Primary Care—Associations with Eosinophilia and Gastrointestinal Symptoms. <i>Pathogens</i> , 2020, 9, 103.	2.8	4
23	British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. <i>Gut</i> , 2020, 69, 984-990.	12.1	232
24	Editorial: quality improvement project to identify factors associated with a delay in IBD diagnosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 733-734.	3.7	0
25	British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. <i>Gut</i> , 2019, 68, s1-s106.	12.1	1,353
26	British Society of Gastroenterology: diagnosis and management of acute lower gastrointestinal bleeding. <i>Frontline Gastroenterology</i> , 2019, 10, 417-420.	1.8	2
27	Monitoring adolescents and young people with inflammatory bowel disease during transition to adult healthcare. <i>Frontline Gastroenterology</i> , 2018, 9, 37-44.	1.8	8
28	Gallstone mimicry: a rare cause of abdominal pain. <i>Gut</i> , 2017, 66, 1251-1251.	12.1	0
29	UK guideline on transition of adolescent and young persons with chronic digestive diseases from paediatric to adult care. <i>Gut</i> , 2017, 66, 988-1000.	12.1	74
30	A career in gastroenterology. <i>BMJ</i> , The, 2016, 353, i1728.	6.0	0